Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




May
15
Today In Oncology
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
FDA Approves Combination Regimen for Newly Diagnosed AML
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo